#HVO hVIVO Plc – Flu B challenge model July 25, 2023 – Posted in: hVIVO (HVO)

£13.1m contract with global pharmaceutical client to develop an influenza B virus challenge model hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces a £13.1m contract with an existing top five global pharmaceutical client to develop an Influenza B (“Flu B”) human challenge model. Highlights · Key prerequisite phase of manufacturing virus is complete · Characterisation trial due to commence in Q4 2023 following completion of…

#ORPH Open Orphan Plc – Capital Markets Day October 20, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces it will be holding a Capital Markets Day for analysts, institutional investors and media on Wednesday 2 November 2022 at 9.30 am – 12.00 pm (GMT). The event, which will be chaired by CEO Yamin ‘Mo’ Khan,…

#HVO hVIVO Plc – Flu B challenge model July 25, 2023 – Posted in: hVIVO (HVO)

#ORPH Open Orphan Plc – Capital Markets Day October 20, 2022 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL